LOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) — On October 17, 2022, Enochian BioSciences, Inc. (the “Company”) obtained a discover (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that as a result of the Company has not but filed its Form 10-Ok, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed firms to well timed file all required periodic monetary studies with the Securities and Exchange Commission (the “SEC”).
This notification has no instant impact on the itemizing of the Company’s shares on Nasdaq. However, if the Company fails to well timed regain compliance with the Nasdaq Listing Rule, the Company’s widespread inventory shall be topic to delisting from Nasdaq.
Under Nasdaq guidelines, the Company has 60 calendar days to both file the Form 10-Ok or to undergo Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If the Company doesn’t file the 10-Ok however submits a plan to regain compliance, and Nasdaq accepts the Company’s plan, then Nasdaq might grant the Company as much as 180 days from the prescribed due date for submitting the Form 10-Ok to regain compliance. If Nasdaq doesn’t settle for the Company’s plan, then the Company can have the chance to enchantment that call to a Nasdaq Hearings Panel.
Forward-Looking Statements
Statements on this press launch that aren’t strictly historic in nature are forward-looking statements. These statements are solely predictions based mostly on present data and expectations and contain a quantity of dangers and uncertainties, together with however not restricted to the success or efficacy of our pipeline. All statements apart from historic information are forward-looking statements, which might be recognized by the use of forward-looking terminology corresponding to “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or related expressions. Actual occasions or outcomes might differ materially from these projected in any of such statements because of varied uncertainties, together with as set forth in Enochian BioSciences’ most up-to-date Annual Report on Form 10-Ok filed with the SEC. Readers are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date hereof. All forward-looking statements are certified of their entirety by this cautionary assertion, and Enochian BioSciences undertakes no obligation to revise or replace this press launch to mirror occasions or circumstances after the date hereof.
Source: Enochian Biosciences
